8-K: Coherus Oncology Changes Auditors

Coherus Oncology, Inc. announced on June 12, 2026, the dismissal of Ernst & Young LLP and the appointment of PricewaterhouseCoopers LLP as its new independent registered public accounting firm.

Summary

• Coherus Oncology, Inc. has dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm, effective June 12, 2026.
• The dismissal of EY did not involve any disagreements on accounting principles or financial statement disclosures.
• A previously reported material weakness in internal control over financial reporting related to inventory account reconciliations for the fiscal year ended December 31, 2024, was remediated as of December 31, 2025.
• PricewaterhouseCoopers LLP (PwC) has been appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to client acceptance procedures.
• There were no prior consultations with PwC regarding matters that would require disclosure under Regulation S-K.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as auditor changes are routine, but the remediation of a material weakness is a positive indicator for financial reporting integrity.

Positives

• The company reported that the material weakness in internal controls over financial reporting has been remediated.
• There were no disagreements with the former auditor, EY, on any accounting principles or financial statement disclosures.

Risks

• Potential disruption or learning curve associated with transitioning to a new auditing firm.
• The previous existence of a material weakness in internal controls, although remediated, could still be a point of scrutiny.

Future Outlook

The appointment of PwC is for the fiscal year ending December 31, 2026, indicating a forward-looking engagement for audit services.

Management Comments

• The Company provided EY with a copy of this Current Report on Form 8-K and requested that EY furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether EY agrees with the statements made herein.

Industry Context

StockSavvy.ai notes that auditor changes are common in the life sciences sector, often occurring after significant financial reporting periods or as companies mature. The transition from EY to PwC, both Big Four accounting firms, suggests a standard business practice rather than an immediate red flag, though the remediation of internal controls is a positive development.

Corporate Governance

Stakeholder Impact

• Shareholders: The change in auditor is a routine governance matter, but the remediation of internal controls is positive for confidence in financial reporting.
• Management: Will need to establish a working relationship with the new audit firm, PwC.
• Regulators: The SEC will review the auditor change and the company's disclosures regarding internal controls.

Next Steps

• PwC will serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard client acceptance procedures.
• Ernst & Young LLP has provided a letter to the SEC agreeing with the statements made in the Form 8-K regarding their dismissal.

Key Dates

Keywords

Coherus Oncology, Form 8-K, Independent Registered Public Accounting Firm, Ernst & Young LLP, PricewaterhouseCoopers LLP, Audit Committee, Internal Controls, Financial Reporting